Taylor King Law is actively investigating GLP-1 lawsuits on behalf of individuals who developed serious health complications after taking popular diabetes and weight-loss drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, and Rybelsus.
Mounting evidence suggests these GLP-1 receptor agonist medications may be linked to vision loss related to NAION and gastroparesis (stomach paralysis) and other severe injuries. Patients in Arkansas and across the U.S. are now pursuing legal action through a GLP-1 lawsuit to seek compensation for their losses.
Contact Personal Injury Attorneys in Arkansas
CNN has reported that physicians are seeing an increase in patients suffering from stomach paralysis after using GLP-1 drugs. Additionally, the U.S. Food and Drug Administration (FDA) has received adverse event reports connecting GLP-1 receptor agonists to gastroparesis and gastric obstruction.
According to CBS News, a GLP-1 lawsuit was filed by a woman who began Ozempic injections in 2022 and later developed severe stomach paralysis. According to her claim, switching to another GLP-1 medication did not resolve her condition.
Many Arkansas GLP-1 lawsuits allege that manufacturers, including Novo Nordisk and Eli Lilly, failed to adequately warn patients and healthcare providers about the heightened risk of gastroparesis and stomach paralysis associated with these drugs.
Further, new studies now suggest patients taking GLP-1 drugs are twice as likely to develop Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
You may be eligible to file a GLP-1 lawsuit in Arkansas if you or a loved one were injured after taking a GLP-1: Ozempic, Wegovy, Mounjaro, Trulicity, Zepbound, or Rybelsus.
You may qualify if you:
Our firm is currently reviewing GLP-1 lawsuit claims involving only specific, medically documented injuries. To be considered for a case evaluation, the following criteria must be met.
We are reviewing cases involving documented diagnoses of:
Your medical records must confirm that you received medical treatment or were hospitalized for one of the above conditions.
To qualify, you must provide evidence that you used a brand-name GLP-1 receptor agonist, such as:
Acceptable proof may include prescription records, medical charts showing the medication was prescribed, or pharmacy packaging labeled with your name.
At this time, we are not reviewing claims involving:
An Arkansas GLP-1 lawsuit may allow injured patients to recover compensation for:
Our Arkansas law firm is committed to holding drug manufacturers accountable and pursuing maximum financial compensation for GLP-1 injury victims.
No Fees Unless We Win
Get In Touch With Us
1-800-305-0529
From June through November 2025, the GLP-1 receptor agonist multidistrict litigation (MDL 3094) expanded rapidly, with the number of pending lawsuits increasing from approximately 1,882 cases in early June to more than 2,900 cases by early November, according to reports from the Judicial Panel on Multidistrict Litigation (JPML).
Throughout this period, the court issued several important rulings shaping the scope of allowable claims. Judge Gene E.K. Marston clarified that plaintiffs may pursue claims involving gastroparesis, provided the condition is supported by objective diagnostic testing, as well as vision-related injuries, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The court also required that gastroparesis claims be confirmed by properly conducted gastric emptying studies.
The litigation continued to broaden in September 2025, with new lawsuits alleging additional gastrointestinal injuries such as ileus, and Eli Lilly filed a motion seeking to centralize federal vision-loss (NAION) claims within MDL 3094 or create a separate MDL under the same judge.
Regulatory developments further intensified scrutiny of GLP-1 drugs. In June 2025, the European Medicines Agency (EMA) formally concluded that semaglutide-containing medications, including Ozempic, Wegovy, and Rybelsus, may cause rare but serious cases of NAION. The EMA reported that semaglutide users faced more than double the risk of developing NAION compared to patients on other diabetes medications and recommended updating drug labels to reflect this risk.
Overall, these developments underscore the rapid growth, expanding scope, and increasing regulatory attention surrounding GLP-1 lawsuits involving gastroparesis and vision loss.
A federal judicial panel has created a new multidistrict litigation (MDL) in Pennsylvania to centralize lawsuits alleging that GLP-1 weight-loss drugs caused vision loss, including NAION, placing the cases before Judge Karen Marston. The panel ruled the vision-loss claims should proceed separately from the existing gastroparesis MDL due to distinct medical and legal issues, despite some overlap. (Reuters)
Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are part of a drug class known as GLP-1 receptor agonists. Wegovy, Ozempic, and Rybelsus contain semaglutide, a compound that mimics a naturally occurring hormone to slow digestion and reduce appetite. Mounjaro and Zepbound contain terzepatide, which works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
While these drugs are effective for blood sugar control and weight loss, slowing stomach emptying may increase the risk of delayed gastric emptying, bezoars, and gastroparesis, and NAION—key issues in many GLP-1 lawsuits.
Gastroparesis is a serious digestive disorder in which the stomach cannot properly move food into the small intestine. Patients often experience chronic nausea, vomiting, bloating, abdominal pain, malnutrition, and unstable blood sugar levels.
There is currently no cure for gastroparesis, and treatments generally provide only limited symptom relief.
The most frequently reported symptoms include:
Gastroparesis can also affect nutrition and blood sugar control, leading to:
In more serious cases, gastroparesis may cause:
Many patients report that symptoms:
Gastroparesis symptoms can be life-altering and, in severe cases, life-threatening. Persistent digestive dysfunction, weight loss, and unstable blood sugar levels often interfere with daily activities, work, and overall quality of life—making gastroparesis a serious injury in GLP-1 lawsuits.
Whether you choose to hire an attorney or not, calling a personal injury attorney in Arkansas will provide you with the information you need to make wise decisions. At Taylor King Law, we’ll listen and then help you explore all your options. Our attorneys answer the question, “Do I have a personal injury case?” every day. You can trust we’ll give you the honest answers you need to decide whether you need representation for your injury claim.
Taylor King
In addition to gastroparesis and stomach paralysis claims, attorneys are now investigating GLP-1 lawsuits involving permanent vision loss, including a serious eye condition known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
NAION occurs when blood flow to the optic nerve is suddenly reduced, causing damage to the nerve that transmits visual information from the eye to the brain. This loss of circulation can result in sudden, painless vision loss, often discovered upon waking.
The optic nerve depends on a steady supply of oxygen-rich blood. In NAION, that blood supply is disrupted—not due to inflammation or a blocked artery, but because of insufficient circulation in the small blood vessels serving the optic nerve.
When this occurs:
In most cases, the vision loss caused by NAION is permanent and irreversible.
Individuals pursuing a GLP-1 lawsuit for vision loss often report symptoms such as:
Although NAION typically affects one eye, patients face an increased risk of the condition occurring in the other eye.
Medical researchers and attorneys are examining whether GLP-1 receptor agonist drugs—including Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound—may increase the risk of NAION in certain patients.
The European Medicines Agency (EMA) has confirmed that Novo Nordisk’s Ozempic and Wegovy may cause non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can lead to permanent vision loss. This marks the first time a regulatory authority has formally recognized the link, reinforcing concerns previously raised in clinical studies. (Reuters)
Known risk factors for NAION include:
Because GLP-1 drugs influence metabolic function, blood sugar levels, and physiological processes that may affect circulation, plaintiffs in GLP-1 lawsuits allege that drug manufacturers knew or should have known about the potential risk of optic nerve damage and failed to adequately warn patients and healthcare providers.
NAION is typically diagnosed by an ophthalmologist or neuro-ophthalmologist through:
There is currently no proven treatment that can reverse optic nerve damage caused by NAION. While some patients experience limited improvement, many are left with lasting visual impairment or blindness, significantly affecting daily life, independence, and employment.
You may qualify for a GLP-1 lawsuit involving NAION if you:
A successful GLP-1 lawsuit involving NAION may allow recovery for:
If you or a loved one developed gastroparesis, stomach paralysis, or NAION-related vision loss after taking a GLP-1 drug, you may have a valid GLP-1 lawsuit.
A free consultation with Taylor King Law can help you understand your legal options and determine whether you qualify for compensation.
Contact Personal Injury Attorneys in Arkansas
Working with a local Arkansas law firm ensures:
If you or a loved one in Arkansas developed gastroparesis, stomach paralysis, gastric obstruction, or permanent vision loss after taking Ozempic, Wegovy, Trulicity, Zepbound, Mounjaro, or Rybelsus, you may have a valid GLP-1 lawsuit.
Call (870) 246-0505 or complete our Free Evaluation Form today. There is no obligation and no upfront cost to learn your legal options.
We’ll be on your side, by your side.
Taylor King
Taylor King opened the first office in 1994 and has been practicing law for more than 30 years. Those who know him best would describe him as “laser-focused,” which is good news for his clients and bad news for his golf opponents.
Memberships & Professional History
Awards and accolades
Client Reviews
What Our Clients Are Saying About Us
6 days ago 
Attorney Chris Cordero was very kind and put me at ease during this process. He always took the time to listen to my concerns. He’s a professional who actually cares about his clients. I highly recommend the Taylor King Law Firm.
1 week ago If you all are ever in need, the people at Taylor King Law are awesome and caring people. They will do their best to get you all that you rightfully deserve; a trusted law firm.
2 weeks ago This law firm is awesome. I appreciate everything they have done for me and my family. I totally recommend them for anyone that is needing a lawyer. My mom was so happy when she found out they were willing to help her. Thank you so much Chad Owens.
View More Reviews on Google Maps.
This page has been written, edited, and reviewed by a team of legal writers following our comprehensive editorial guidelines. This page was approved by attorney Taylor King, who opened the firm’s first office in 1994 and has been practicing law for more than 30 years.
Please describe your accident and the injuries you sustained. One of our experienced injury lawyers will contact you for a free case evaluation. If we’re able to assist and you’re unable to travel, we can meet you at your home, workplace, or hospital.
call for a free consultation
820 W 3rd Street
Little Rock, AR 72201
Phone: 501.712.2554
Toll-Free: 1.877.455.4790
Fax: 870.246.0529
410 N Thompson Street, Suite B
Springdale, AR 72764
Phone: 479.935.1761
Toll-Free: 1.877.283.1274
Fax: 870.293.2475
320 Main Street
Arkadelphia, AR 71923
Phone: 870.246.0505
Toll-Free: 1.877.665.0873
Fax: 870.246.0529
2620 Prince Street
Conway, AR 72034
Phone: 501.712.2554
Toll-Free: 1.877.696.8695
Fax: 870.246.0529
1920 East Matthews Avenue
Jonesboro, AR 72401
Phone: 870.568.1158
Toll-Free: 1.877.589.2660
Fax: 870.520.5099
3801 Rogers Avenue
Fort Smith, AR 72903
Phone: 479.668.3198
Toll-Free: 1.877.899.3202
Fax: 479.234.4216
call 
message